Next Article in Journal
Inside the Cell: Integrins as New Governors of Nuclear Alterations?
Next Article in Special Issue
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Previous Article in Journal
Roles of Integrin α6β4 Glycosylation in Cancer
Previous Article in Special Issue
Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Cancers 2017, 9(7), 81;

The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Author to whom correspondence should be addressed.
Academic Editor: Eddy S. Yang
Received: 19 June 2017 / Revised: 30 June 2017 / Accepted: 3 July 2017 / Published: 6 July 2017
(This article belongs to the Special Issue DNA Repair Pathways in Cancer)
Full-Text   |   PDF [897 KB, uploaded 6 July 2017]   |  


DNA double-strand breaks (DSBs) are deleterious DNA lesions that if left unrepaired or are misrepaired, potentially result in chromosomal aberrations, known drivers of carcinogenesis. Pathways that direct the repair of DSBs are traditionally believed to be guardians of the genome as they protect cells from genomic instability. The prominent DSB repair pathway in human cells is the non-homologous end joining (NHEJ) pathway, which mediates template-independent re-ligation of the broken DNA molecule and is active in all phases of the cell cycle. Its role as a guardian of the genome is supported by the fact that defects in NHEJ lead to increased sensitivity to agents that induce DSBs and an increased frequency of chromosomal aberrations. Conversely, evidence from tumors and tumor cell lines has emerged that NHEJ also promotes chromosomal aberrations and genomic instability, particularly in cells that have a defect in one of the other DSB repair pathways. Collectively, the data present a conundrum: how can a single pathway both suppress and promote carcinogenesis? In this review, we will examine NHEJ’s role as both a guardian and a disruptor of the genome and explain how underlying genetic context not only dictates whether NHEJ promotes or suppresses carcinogenesis, but also how it alters the response of tumors to conventional therapeutics. View Full-Text
Keywords: NHEJ; cancer; genomic instability; carcinogenesis; cancer therapy; DSB repair NHEJ; cancer; genomic instability; carcinogenesis; cancer therapy; DSB repair

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Sishc, B.J.; Davis, A.J. The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers 2017, 9, 81.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top